Cipla's InvaGen US facility inspection classified as Voluntary Action Indicated (VAI) by USFDA
Cipla's subsidiary, InvaGen Pharmaceuticals Inc., has received a Voluntary Action Indicated (VAI) classification from the USFDA for its US facility inspection. The inspection occurred from July 13-17, 2026, with the classification communicated on August 28, 2026.
A VAI classification is generally positive and suggests that the facility's operations are largely compliant. However, any regulatory inspection outcome can have a moderate impact on investor confidence and future operational considerations.
The classification of 'Voluntary Action Indicated' (VAI) by the USFDA is a positive outcome, indicating that while observations were made, no significant issues requiring immediate mandatory action were found. This is generally viewed favorably by the market.
Cipla Limited has announced an update regarding the United States Food and Drug Administration (USFDA) inspection conducted at the Unit 3 manufacturing facility of its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc. The facility is located in Central Islip, Long Island, New York, USA.
The inspection took place from 13th July, 2026, to 17th July, 2026 (EDT). Following this, the USFDA, via a communication dated 28th August, 2026, has classified the inspection as Voluntary Action Indicated (VAI).
This classification was communicated to Cipla Limited on 28th August, 2026. The company has duly notified the stock exchanges, including BSE Limited, the National Stock Exchange of India Limited, and Societe de la Bourse de Luxembourg.
A plain-language summary of a public exchange filing by Cipla Limited. Read the original for the full detail.